Compare XPER & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XPER | IPSC |
|---|---|---|
| Founded | 1990 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 395.8M | 405.8M |
| IPO Year | 2021 | 2021 |
| Metric | XPER | IPSC |
|---|---|---|
| Price | $7.83 | $1.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $11.67 | $4.25 |
| AVG Volume (30 Days) | 302.8K | ★ 917.1K |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.30 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $448,105,000.00 | $109,164,000.00 |
| Revenue This Year | $4.03 | N/A |
| Revenue Next Year | $8.11 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 1556.76 |
| 52 Week Low | $5.07 | $0.44 |
| 52 Week High | $8.75 | $2.97 |
| Indicator | XPER | IPSC |
|---|---|---|
| Relative Strength Index (RSI) | 53.73 | 39.99 |
| Support Level | $7.58 | $1.96 |
| Resistance Level | $8.08 | $2.62 |
| Average True Range (ATR) | 0.27 | 0.12 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 75.30 | 8.54 |
Xperi Inc is a media and entertainment technology company. Its technologies are integrated into consumer devices, connected cars, and a variety of media platforms globally, enabling audiences to connect with entertainment content in a more intelligent, immersive, and personal way. As its audiences engage with content on the platform, the company operates a cross-screen advertising solution that enables brands to reach millions of engaged consumers across rapidly expanding digital entertainment ecosystem. It operates in one reportable business segment and group its revenue into four categories: Pay-TV, Consumer Electronics, Connected Car and Media Platform. Geographically it operates in U.S. and Canada, Asia Pacific, Europe, Middle East and Africa, and Other countries.
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.